Page Updated May 29, 2024

Jeffrey P. Ward, MD, PhD

Page Written by

Terri Heimann Oppenheimer

Page Edited by Patient Advocate

Dave Foster

Fact Checked

Dr. Jeffrey P. Ward is a physician-scientist at the Siteman Cancer Center and Washington University School of Medicine with a particular interest in thoracic oncology. His patient care is focused on treating patients diagnosed with lung cancer and other thoracic malignancies. He works to leverage innovations, including immunotherapy treatments, to develop better strategies that arm the immune system to effectively control lung cancer.[1]

Dr. Ward is aware of the uncertainty that patients carry into their appointments with him and is proud that he and the multidisciplinary team that he works with can offer so many new options for treatment and improved outcomes.

Education and Career

Dr. Ward earned his medical degree and his Ph.D. in Immunology at the State University of New York Medical University in Syracuse, New York. He completed his internship and residency in Internal Medicine at Barnes-Jewish Hospital in St. Louis, Missouri, then completed a fellowship in Medical Oncology at the Washington University School of Medicine.[1]

Research

Dr. Ward’s research interests include the clinical development and introduction into practice of checkpoint inhibitors that reinvigorate the immune system.  

Dr. Ward’s recent publications include:[1]

• Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study. Leal T, Kotecha R, Ramlau R, […] Ward J, […] Langer C. Lancet Oncol 2023
• BHLHE40 Regulates the T-Cell Effector Function Required for Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy. Salmon AJ, Shavkunov AS, Miao Q, […] Ward JP, […] Gubin MM. Cancer Immunol Res 2022
• Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma. Ward J, Berrien-Elliott MM, Gomez F, […] Bartlett NL. Blood 2022
• Genomic Profiling of Lung Adenocarcinoma in Never-Smokers. Devarakonda S, Li Y, Martins Rodrigues F, […] Ward J, […] Govindan R. J Clin Oncol 2021
• Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. Lussier DM, Alspach E, Ward JP, […] Schreiber R. Proc Natl Acad Sci USA 2021

Terri Heimann Oppenheimer

Writer

Terri Oppenheimer has been writing about mesothelioma and asbestos topics for over ten years. She has a degree in English from the College of William and Mary. Terri’s experience as the head writer of our Mesothelioma.net news blog gives her a wealth of knowledge which she brings to all Mesothelioma.net articles she authors.

Connect with Terri Heimann Oppenheimer

Dave Foster

Page Editor

Dave has been a mesothelioma Patient Advocate for over 10 years. He consistently attends all major national and international mesothelioma meetings. In doing so, he is able to stay on top of the latest treatments, clinical trials, and research results. He also personally meets with mesothelioma patients and their families and connects them with the best medical specialists and legal representatives available.

Connect with Dave Foster